China Nuokang Bio-Pharma Falls on NY Debut
By wchung | 08 Jun, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Recent Articles
- China May Exports Pegged for Strong Growth on Front-Loaded Orders, Chip Demand
- China's Global E-Commerce Slides as Iran War Lifts Costs, Dampens Demand
- S. Korea to Seek Priority Supply of Nvidia Vera Rubin GPUs
- VinFast Q1 Revenue Surge on Strong Southeast Asia EV Demand
- KOSPI Plunges on Fed Rate Hike Bet
- Nvidia Clinches Pacts with S. Korean Tech Giants Deep into the AI Boom
- Gwynne Shotwell Manifested Musk's Lofty SpaceX IPO
- Lip-Bu Tan's Intel Eyed to Make Three Million Custom AI Chips for Google
- Cerebras Gets Street Behind Its Unique Dinner-Plate AI Chips
- Election Betting Boom to Test US Insider Trading Controls for Prediction Markets